Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Content from other channels on our network

National standards for pain management education now available

Daniel Wyner appointed Lumary CEO

Home care safeguards when disasters hit

"Historic legislation" allows authorised nurses to prescribe PBS medicines

You see what others miss

Microbubbles remove microplastics from wastewater

Partnership boosts bio-based graphite material deployment

New way to recycle coloured plastics using silica microspheres

Demand increases for skilled sustainability professionals

Pilot program reduces food waste in SEQ

Sydney University signs agrifood innovation agreement with FAO

interpack 2029 will have a new runtime

Jet Technologies partners with coffee processing specialist Neuhaus Neotec

Arla Foods acquires Aussie cottage cheese producer

Ferrero appoints new GM to lead Australia and NZ